Sirolimus-eluting coronary stents: a review

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Sirolimus-eluting coronary stents gained European (2002) and US (2003) approval.
• Sirolimus, a macrolide antibiotic, exhibits potent antiproliferative properties against smooth muscle cells.
• Early studies highlighted the stent's potential, leading to further clinical investigation.

Purpose of the Study:

• To review the clinical evidence supporting sirolimus-eluting coronary stents.
• To assess the stent's efficacy in complex lesions and high-risk patients.
• To compare available drug-eluting stent technologies.

Main Methods:

• Analysis of randomized, controlled trials.
• Inclusion of data from studies on complex lesions (in-stent restenosis, small vessels, CTOs).
• Evaluation of trials involving high-risk patients (e.g., diabetics).
• Review of head-to-head comparisons between drug-eluting stents.

Main Results:

• Documented profound antiproliferative effects of sirolimus.
• Demonstrated efficacy in complex lesion subsets and diabetic patients.
• Head-to-head trials provided comparative data on drug-eluting stents.
• Numerous studies confirmed safety and efficacy, improving patient outcomes.

Conclusions:

• A substantial body of evidence supports the use of sirolimus-eluting coronary stents.
• This technology leads to significantly improved patient outcomes post-percutaneous intervention.
• The interventional cardiology community has strong evidence for the stent's benefits.